Before the Chinese National Day holiday, NINGBO SCIENTZ Biotechnology announced that the company will be listed on the Beijing Stock Exchange on October 10, 2022. The issue price of NINGBO SCIENTZ Biotechnology is 15 CNY per share, and the issue price-earnings ratio is 30.12 times. It is known as the "first share of scientific instruments" on the Beijing Stock Exchange.

As a leading enterprise in China's life science equipment market, NINGBO SCIENTZ Biotechnology has landed in the capital market at a lightning speed, which on the one hand shows its hard power, on the other hand, it may also indicate that it will capture more investors in the future.

The industry is growing rapidly

Among the three product lines of NINGBO SCIENTZ Biotechnology, biological sample processing products are the mainstay of their revenue. From 2019 to 2021, the revenue of this product will account for 64.03%, 63.01% and 62.04%, respectively.

According to Frost & Sullivan data, in 2019, the global pharmaceutical market was worth US$1.32 trillion, and it is expected that this figure will grow to US$1.64 trillion by 2024. From 2019 to 2024, the CAGR of the relevant market is 4.4%.

Core competitiveness to capture high-quality customers

As of 2021, NINGBO SCIENTZ Biotechnology has been authorized 62 patented technologies, including 15 invention patents, 41 utility model patents, 6 design patents, and 24 software copyrights. Many of its technologies have reached the domestic leading and international advanced level. For example, "China Science News" once reported that the high-pressure gas gene gun developed by NINGBO SCIENTZ Biotechnology "breaks the monopoly of foreign technology in one fell swoop and fills the gap in related domestic fields". In 2021, it was selected into the third batch of "specialized, special, and new little giants" by the Ministry of Industry and Information Technology, and was recognized as "Ningbo Manufacturing Single Champion Demonstration Enterprise" by Ningbo Bureau of Economy and Information Technology.

A major advantage brought by the recognition of professional institutions is that NINGBO SCIENTZ Biotechnology can capture professional-level customers.

Orderly expansion of production

According to the financial report, in the first half of 2022, the revenue of NINGBO SCIENTZ Biotechnology and Drug Research Instruments increased by 179.41%. But it is worth noting that the gross profit margin of this business also fell sharply by 37.27%.

In fact, part of the reason for NINGBO SCIENTZ Biotechnology 's impact on IPO is to increase production capacity. The "Prospectus" shows that NINGBO SCIENTZ Biotechnology plans to raise 440 million yuan, of which 244 million yuan will be used for life science instrument industrialization construction projects, accounting for more than half.

It is reported that after the completion of the project, the production capacity of NINGBO SCIENTZ Biotechnology's "molecular biology and drug research instruments, biological sample processing instruments, laboratory automation and general equipment will be significantly increased compared to the company's existing production capacity.